Clinical Trials Directory

Trials / Sponsors / Resverlogix Corp

Resverlogix Corp

Industry · 11 registered clinical trials — 2 currently recruiting.

StatusTrialPhaseStarted
RecruitingA Study of Apabetalone in Subjects With Long -COVID
Post-Acute COVID-19 Syndrome
Phase 2 / Phase 32025-04-15
Not Yet RecruitingA Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis
Kidney Failure, Chronic
Phase 1 / Phase 22024-11-22
WithdrawnSafety and Effect of Oral RVX000222 in Subjects With Fabry Disease
Fabry Disease
Phase 1 / Phase 22022-11-22
TerminatedAn Open-Label Study of Apabetalone in Covid Infection
COVID-19 Infection
Phase 2 / Phase 32022-01-14
CompletedEffect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
Diabetes Mellitus, Type 2, Coronary Artery Disease
Phase 32015-11-01
TerminatedCharacterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia
Dyslipidemia, Coronary Artery Disease
Phase 22013-05-01
CompletedThe Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes
Diabetes
Phase 22012-11-01
CompletedApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation
Coronary Artery Disease
Phase 22011-09-01
CompletedThe Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation
Coronary Artery Disease, Dyslipidemia
Phase 22011-08-01
CompletedClinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease
Atherosclerosis, Coronary Artery Disease
Phase 22009-12-01
CompletedSafety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome
Phase 1 / Phase 22008-09-01